Weekly Top Ten News Stories – 11 October 2019

Going nowhere. Uranium prices continue to rise and fall but it remains a case of failure to launch.

A new report reveals what investors may already know, that "fees make all the difference" to final outcomes for superannuation members' retirement savings, with many funds struggling to generate returns strong enough to cover the negative impact of high investment fees.

A new specialty female oral contraceptive will grace the portfolio of Mayne Pharma, providing a substantial growth opportunity in the medium-long term.

As a record low cash rate prevails, amid weak consumer and business sentiment and only muted improvements in housing activity, Australia's major banks are being squeezed mercilessly.

The New Criterion's Tim Boreham highlights several listed "penny dreadfuls" that may prove not to be so dreadful after all.

The New Criterion's Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world's foremost pain medication.

Weekly Broker Wrap: petrol; infant formula; housing & cash rates; wealth managers; platforms; and childcare.

The Chartist suggests recent consolidation for the iron ore price implies risk remains to the upside.

EclipX Group is reverting to focus on its core fleet and novated leasing businesses, and interest in the company is only expected to grow.

Weekly update on stockbroker recommendation, target price, and earnings forecast changes.